The FDA is signaling a potentially important shift in how it approaches rare disease drug development and review. Through its new Rare Disease Framework Initiative, announced on October 14, 2026, the agency aims to establish a more consistent regulatory approach in which evidentiary expectations are tailored to what is reasonably attainable given the disease, patient population, patient needs, and characteristics of the investigational product.[1] This shift comes at a time when the agency reports that, as of 2025, only approximately 5% of recognized rare diseases had an FDA-approved treatment.[2]
The initiative also creates an opportunity for rare disease drug developers, patient advocates, and other stakeholders to help shape the FDA’s future regulatory approach. On October 16, 2026, the FDA published a Federal Register notice announcing a hybrid public meeting on October 28, 2026, and a public docket for written comments through December 11, 2026.[3] The initiative is led by the FDA’s Rare Disease Innovation Hub in coordination with the Office of the Commissioner, the Center for Biologics Evaluation and Research (CBER), and the Center for Drug Evaluation and Research (CDER).[4]
Why Is the FDA Reconsidering Its Approach to Rare Disease Drug Development?
The initiative addresses a persistent problem for rare disease developers: traditional drug development tools do not always translate neatly to very small patient populations. The FDA acknowledges challenges including limited natural-history data, geographically dispersed patients, disease heterogeneity, and the absence of validated biomarkers or clinical outcome assessments.[5] The agency recognizes that these challenges require regulatory approaches tailored to the evidence that can reasonably be generated, the characteristics of the investigational product, and the needs of affected patients.
The scale of the problem is considerable: roughly one in ten Americans lives with a rare disease,[6] and the Federal Food, Drug, and Cosmetic Act (FDCA) generally defines a rare disease or condition as one that affects fewer than 200,000 people in the United States.[7] The FDA also reports that about half of CDER’s and CBER’s recent novel drug approvals have been for rare diseases, yet the agency acknowledges that the pace of progress has not matched the scale of the need.[8]
Importantly, the initiative does not change the governing legal standard. Approval under the FDCA still requires substantial evidence of effectiveness from adequate and well-controlled investigations,[9] and the FDA states that the framework will continue to adhere fully to the statutory requirements of safety and effectiveness.[10]
How the New Framework Builds on the FDA’s Existing Rare Disease Initiatives
The framework follows a series of FDA announcements over the past year. In September 2025, CDER and CBER introduced the Rare Disease Evidence Principles (RDEP), a process for drugs intended to treat very small patient populations (generally fewer than 1,000 people in the United States) with a known, in-born genetic defect that is the major driver of the disease.
Under RDEP, the FDA expects that substantial evidence of effectiveness may generally be established through one adequate and well-controlled study, which may be a single-arm trial, together with robust confirmatory evidence. That evidence may include data on the drug’s effect on the direct pathophysiology of the disease, relevant nonclinical models, clinical pharmacodynamic data, case reports and expanded access data, and external controls or natural history studies. Sponsors may apply at any time before launching a pivotal trial, and RDEP does not displace the statutory approval standard.[11]
In February 2026, the FDA issued draft guidance on a “plausible mechanism” framework for individualized therapies, such as genome-editing and RNA-based products, that target specific genetic conditions with a known biological cause. The comment period closed on April 27, 2026.[12] FDA leadership has also publicly stated that, for novel drugs generally, one adequate and well-controlled trial supported by confirmatory evidence will be the default expectation, an approach the FDA first described in a September 2023 draft guidance.[13]
These actions suggest that the framework is intended to systematize flexibility that the FDA has so far offered through discrete programs. The FDA itself acknowledges that a 2024 Government Accountability Office report identified 18 rare disease programs at the agency, most launched since 2019, and describes the framework as an effort to build on, systematize, and operationalize those efforts in a consistent, cross-center approach.[14]
What Could the FDA’s Rare Disease Framework Mean for Drug Developers?
1. Greater clarity and consistency.
The FDA wants greater clarity, consistency, and predictability in regulatory decision-making. The initiative calls for better coordination of rare disease expertise across the agency and more consistent application of tailored approaches across review divisions. The FDA also intends to embed the patient voice early and at defined milestones, and to rely more heavily on external disease experts, as a structural feature of review.[15]
2. Innovative evidence generation.
The FDA is explicitly emphasizing cutting-edge science, novel clinical trial designs, and innovative statistical approaches. The agency also highlights genomic characterization, platform trials, real-world evidence methodologies, and Bayesian statistical approaches as relevant to small population settings. The FDA states that advances in these areas have expanded what is scientifically achievable.[16]
3. Implications beyond trial design.
The framework’s scope extends from pre-investigational (pre-IND) interactions through post-approval obligations and chemistry, manufacturing, and controls (CMC) requirements. The FDA also identifies risk-based approaches to CMC review and preapproval inspections as an area that could support earlier patient access without compromising quality, safety, or effectiveness.[17] CMC is also one of four focus areas on which the FDA has asked the public to comment.[18]
4. Opportunities to shape the framework.
The FDA has scheduled a public meeting for October 28, 2026, and opened a public comment docket (FDA-2026-N-12214) with a submission deadline of December 11, 2026. It also plans sector-specific roundtables and internal agency feedback sessions.[19] Commenters are asked to address four topics: fit-for-purpose review based on attainable evidence, disease state, and patient population; consistency and predictability of regulatory requirements; engagement with patients, disease experts, and researchers; and CMC considerations specific to rare disease therapies.[20] Roundtables will be targeted to drug developers, patient advocacy organizations, academic researchers, and clinicians.[21] Potential outcomes include revisions to regulations, updated or new guidance, greater alignment between CDER and CBER, and reviewer training.[22]
Sponsors should keep two limits in mind. First, the framework is at an early, input-gathering stage, and the FDA has not said when it will propose regulatory or guidance changes. Second, tailored evidentiary expectations must still satisfy the statutory standards for safety and effectiveness, and the FDA has cautioned that its concurrence on study design and confirmatory evidence under RDEP does not necessarily mean a drug will be found approvable.[23]
If the FDA succeeds in translating these principles into consistent review practices, the result could be a rare disease regulatory system better calibrated to the scientific realities of developing therapies for very small patient populations, while preserving the statutory standards for safety and effectiveness.
Key Takeaways for Rare Disease Drug Developers
Rare disease developers should view the initiative not merely as another FDA program, but as an opportunity to help shape how regulatory flexibility is operationalized. Sponsors confronting difficult endpoint, natural history, statistical, CMC, or small-population questions may have particularly valuable perspectives to contribute through the FDA’s public meeting, written comment process, and planned stakeholder roundtables.
Developers should consider the following steps:
- Evaluate how the proposed framework could affect existing or planned clinical development programs, particularly those involving small patient populations or limited natural-history data.
- Identify evidentiary, statistical, or manufacturing challenges that may warrant greater regulatory flexibility or clarification.
- Consider submitting comments to the FDA by December 11, 2026, to help inform the development of the framework.
- Monitor subsequent FDA guidance, regulatory proposals, and implementation activities for potential implications for development and approval strategies.
How Frier Levitt Can Help
Frier Levitt advises rare disease drug developers and life sciences companies on FDA regulatory strategy, compliance, and policy initiatives including developments related to the FDA’s Rare Disease Framework Initiative. Our attorneys can assist sponsors in evaluating the initiative’s potential impact on their development programs, preparing comments for the FDA, and navigating evolving regulatory expectations as the agency considers changes to its guidance, regulations, and review processes.
[1] FDA, A New Framework for Rare Disease Review (Oct. 2026), https://www.fda.gov/media/195694/download [hereinafter White Paper]; see also FDA, Rare Disease Framework, https://www.fda.gov/industry/fda-rare-disease-innovation-hub/rare-disease-framework (content current as of Oct. 14, 2026).
[2] White Paper at 3.
[3] Fit-for-Purpose Rare Disease Framework Initiative; Public Meeting; Request for Information and Comments, 91 Fed. Reg. 65,750 (Oct. 16, 2026) (Docket No. FDA-2026-N-12214) [hereinafter FR Notice], at 65,750–51.
[4] FR Notice at 65,751; White Paper at 9.
[5] White Paper at 4–5.
[6] FR Notice at 65,751; White Paper at 3.
[7] 21 U.S.C. § 360bb(a)(2); see White Paper at 4.
[8] White Paper at 3.
[9] 21 U.S.C. § 355(d); 21 C.F.R. § 314.126.
[10] White Paper at 3, 7.
[11] FDA, CDER/CBER Rare Disease Evidence Principles (RDEP) (Sept. 3, 2025), https://www.fda.gov/industry/fda-rare-disease-innovation-hub/cdercber-rare-disease-evidence-principles-rdep [hereinafter RDEP] (stating that drugs in the process “will continue to be reviewed under the statutory marketing approval standard of safety and efficacy pursuant to 505(d) of the FDCA”).
[12] FDA, Draft Guidance for Industry, Considerations for the Use of the Plausible Mechanism Framework To Develop Individualized Therapies That Target Specific Genetic Conditions With Known Biological Cause (Feb. 2026), https://www.fda.gov/media/191247/download; Notice of Availability, 91 Fed. Reg. 9283 (Feb. 25, 2026) (Docket No. FDA-2026-D-1256) (comments due Apr. 27, 2026).
[13] Marty Makary & Vinay Prasad, N. Engl. J. Med. (Feb. 2026), doi:10.1056/NEJMsb2517623; see also FDA, Draft Guidance for Industry, Demonstrating Substantial Evidence of Effectiveness With One Adequate and Well-Controlled Clinical Investigation and Confirmatory Evidence (Sept. 2023), https://www.fda.gov/regulatory-information/search-fda-guidance-documents/demonstrating-substantial-evidence-effectiveness-one-adequate-and-well-controlled-clinical.
[14] White Paper at 5 (citing a 2024 U.S. Government Accountability Office report).
[15] FR Notice at 65,751; White Paper at 8.
[16] White Paper at 9–10.
[17] White Paper at 7–8; FR Notice at 65,751.
[18] FR Notice at 65,752.
[19] FR Notice at 65,750–52; FDA, FDA Rare Disease Framework Initiative Public Meeting (Oct. 28, 2026), https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/fda-rare-disease-framework-initiative-public-meeting-10282026.
[20] FR Notice at 65,752.
[21] White Paper at 8.
[22] White Paper at 9.
[23] RDEP, supra note 11 (stating that FDA’s concurrence on study design and qualifying confirmatory evidence “would not necessarily indicate that the Agency expects to determine that the drug is approvable”); White Paper at 7.
Partner, Chair of the FDA Practice
